Is Ozempic considered natty?

Ozempic is generally regarded as compatible with natural bodybuilding. Most sanctioning bodies do not prohibit its therapeutic use, though rules vary by federation.

Is Ozempic on the WADA prohibited list?

As of the current prohibited list, Ozempic is not explicitly banned by WADA, though regulations can change. Always verify against the current year's WADA prohibited list before competition.

How is Ozempic administered?

Ozempic is typically administered via: subcutaneous injection, oral. Dosage and administration protocols vary; see the Dosage section for details.

Ozempic - Retapedia | Natty or Not?

Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Ozempic
Structure of Ozempic. 31-aa GLP-1 analog with Aib² and Arg³⁴ substitutions and γGlu–2×OEG–C18 diacid lipidation on Lys26. Source: Wikimedia Commons.
Identification
Class	Modified peptide
PubChem CID	56843331
Other names	Semaglutide · GLP-1 agonist
Trade names	Ozempic Wegovy Rybelsus
Administration
Routes	Subcutaneous injection Oral
Status
Verdict	Natty
WADA	Not prohibited^[9]
Article meta
Slug	`semaglutide`
Last edited	June 3, 2026
Tags	fat loss, weight loss, cardiovascular, diabetes, oral, subcutaneous

Ozempic (also known as Semaglutide or GLP-1 agonist) is a therapeutically researched peptide studied for its effects on fat loss, weight loss, cardiovascular. FDA-approved GLP-1 agonist (Ozempic/Wegovy/Rybelsus) with 15-21% weight loss and 20% cardiovascular risk reduction. Nausea common, NAION risk noted.

Semaglutide is an FDA-approved GLP-1 receptor agonist with 94% structural homology to human GLP-1, manufactured by Novo Nordisk as Ozempic (diabetes, 0.25-2mg weekly injection), Wegovy (obesity, up to 2.4mg weekly injection), and Rybelsus (diabetes, 3-14mg daily oral). Activates GLP-1 receptors in the gastrointestinal tract, pancreas, and brain to reduce appetite, delay gastric emptying, increase insulin release, and lower glucagon secretion. STEP trials demonstrated 14.9-17.4% mean weight loss at 68 weeks (2.4mg dose), with 69-79% achieving ≥10% weight loss.

Natty status

Ozempic is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.

Contents [hide]

1 Overview
2 Mechanism of action
3 Reported effects
4 Dosage and administration
5 Natty status
6 Research
7 Related compounds
8 References
9 External links

Overview

STEP UP trial showed 20.7% weight loss with 7.2mg dose at 72 weeks.

SELECT cardiovascular outcomes trial showed 20% reduction in major adverse cardiac events (HR 0.80) in patients with obesity and preexisting cardiovascular disease but without diabetes.

FDA-approved March 2024 for reducing cardiovascular death, heart attack, and stroke risk.

Also approved for metabolic-associated steatohepatitis (MASH).

Most common side effects are gastrointestinal (nausea affecting up to 20%, vomiting, diarrhea, constipation), typically transient and mild-to-moderate.

Notable concerns include possible gastroparesis, 85% increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), and thyroid cancer warnings from rodent studies (though human incidence <1%).

Available in both injection (89% bioavailability) and oral forms (0.4-1% bioavailability).

Gradual titration over 12-16 weeks minimizes gastrointestinal side effects.

Mechanism of action

Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.

Reported effects

Effects reported in the literature and from preclinical models include:

Semaglutide 2.4mg weekly produced an 11.45% body weight reduction versus placebo in a network meta-analysis of 6 RCTs (4,642 participants) in adults with overweight or obesity without diabetes. ^[4] Phase III
Once-daily oral semaglutide demonstrated superior body weight loss versus placebo in adults with overweight or obesity across the OASIS 1, 2, and 4 trials, securing FDA approval for oral Wegovy. ^[8] Phase III
GLP-1 receptor agonists including semaglutide reduce liver fat content, improve liver enzyme profiles, and produce favorable histologic changes in MASLD/MASH via hepatic lipid metabolism and anti-fibrogenic mechanisms. ^[5] Phase II
Semaglutide is FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, with proposed mechanisms including anti-inflammatory, antioxidant, and anti-apoptotic actions. ^[6]^[3] FDA approved
Semaglutide use in type 2 diabetes is associated with a significantly increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), with pooled hazard ratios of 2.37-3.36 across retrospective cohorts and an 85% increased risk versus SGLT2i initiators in a target trial emulation study. ^[7]^[1] Phase III
Preoperative semaglutide use in type 2 diabetes patients undergoing open carpal tunnel release reduced odds of surgical site infection (OR 0.31), wound dehiscence (OR 0.25), and sepsis (OR 0.61) in a matched retrospective cohort of 1,673 patients. ^[2] Phase II

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Dosage and administration

⚠

Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

Injectable

Week 1-4: 0.25mg once weekly (subcutaneous)
Week 5-8: 0.5mg once weekly
Week 9-12: 1.0mg once weekly
Week 13+: 2.0mg (Ozempic) or 2.4mg (Wegovy) maximum
Higher dose: 7.2mg weekly (experimental, 20.7% weight loss)

Oral Rybelsus

Days 1-30: 3mg daily on empty stomach
Days 31-60: 7mg daily
Day 61+: 14mg daily maximum

General

Take oral form with ≤4oz water, wait 30 min before eating
Gradual titration over 12-16 weeks reduces GI side effects

Natty status

See also: Peptide § Natty status

Ozempic is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.^[9]